U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07309380) titled 'Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D' on Dec. 16.
Brief Summary: This study adopts a multicenter, randomized, double-blind, placebo-parallel controlled design to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D.
A total of 150 subjects are planned to be enrolled. After passing the screening, they will be randomly assigned to the L47 group or the placebo group at a ratio of 2:1, with liver cirrhosis and subjects' regional distribution as stratification factors. The two groups will receive hepratide (2.1 mg/day) or placebo, respectively. Upon completion of the 48-w...